IPM Take
A high response rate can change the mood in oncology. It cannot, on its own, change the standard of care. The calderasib data reinforce a central precision-medicine lesson: the mutation matters, the combination matters, and the treatment line matters. But the real test is whether a more intensive molecular strategy can deliver durable benefit without creating a new toxicity and access burden.
Executive Summary
Updated Phase I KANDLELIT-001 data presented at the ESMO Gastrointestinal Cancers Congress in Munich showed growing activity for calderasib, an investigational KRAS G12C inhibitor, in advanced colorectal cancer. Reported objective response rates were 34% with calderasib alone, 46% with calderasib plus cetuximab, and 77% with calderasib, cetuximab and chemotherapy. In the frontline subgroup receiving the triplet, the reported response rate was 87%. Grade 3–4 treatment-related adverse events increased from 9% with monotherapy to 42% with the triplet, while a Phase III trial is now recruiting.
Why it matters
- Patients / advocates: A chemotherapy-free or chemotherapy-light targeted approach remains attractive, but early response is not the same as durable survival benefit.
- Clinicians: The data strengthen the rationale for dual KRAS–EGFR blockade and raise fresh questions about when combination intensity is justified.
- Diagnostics / pathology: A KRAS G12C result is becoming more operationally important, making rapid and reliable molecular testing essential.
- Payers and HTA bodies: If the combination advances, assessment will need to look beyond response rates to toxicity, sequencing, duration of benefit and service burden.
A 77% response rate gets attention. It should not get a free pass.
At ESMO GI this weekend, updated results from the ongoing KANDLELIT-001 study gave colorectal-cancer specialists a sharper look at calderasib, Merck’s next-generation KRAS G12C inhibitor. The pattern is clear: activity increased as treatment intensified. Response rates rose from 34% with calderasib alone to 46% with calderasib plus cetuximab, then to 77% when chemotherapy joined the combination. Among patients receiving the triplet in the frontline setting, the reported response rate reached 87%.
That is not a minor signal. KRAS G12C-mutated colorectal cancer remains a difficult molecular subgroup, and the biology explains why this type of combination is attractive. KRAS inhibition can trigger feedback through the EGFR pathway. Adding an EGFR inhibitor such as cetuximab is therefore not an afterthought; it is part of the strategy to stop the tumour finding another route around the blockade.
But this is where a credible precision-oncology platform needs to stay disciplined.
KANDLELIT-001 is still an early-phase study. Median progression-free survival had not been reached in the frontline triplet group, but the data remain immature. More importantly, efficacy came with a cost: Grade 3–4 treatment-related adverse events increased to 42% with the triplet, compared with 9% for calderasib alone and 20% for the doublet.
That does not make the result disappointing. It makes the next question unavoidable: which patients need the full triplet, which could benefit from a less intensive regimen, and how will systems identify them early enough for the treatment to matter?
The answer will not come from a press release or a conference slide. It will come from the Phase III programme, longer follow-up, cleaner evidence on survival and quality of life, and molecular diagnostics that do not leave patients waiting while their disease moves faster than the pathway.
